Physician profile
William Eugene Loper
NPI 1881601409
$9,362.08
in general payments reported to CMS, 2019-2025
42 companies · $988 in 2025
The $988 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,729 · 2020: $1,333 · 2021: $1,393 · 2022: $1,518 · 2023: $1,249 · 2024: $1,152 · 2025: $988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,389.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,373.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,303.11 | 2019-2025 | |
| Abbvie INC. | $1,073.29 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $550.36 | 2019-2023 | Steglatro, Belsomra, Verquvo |
| Abbott Laboratories | $540.00 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Amgen INC. | $465.48 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $445.49 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Novartis Pharmaceuticals Corporation | $422.18 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $411.25 | 2019-2024 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $349.43 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $293.32 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.86 | 2021-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.25 | 2019-2025 | Jardiance |
| Allergan, INC. | $202.01 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $150.86 | 2019-2021 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $120.57 | 2021-2022 | |
| Amarin Pharma, INC. | $113.64 | 2019-2020 | |
| Esperion Therapeutics, INC. | $104.89 | 2021-2024 | Nexletol |
| Biohaven Pharmaceutical Holding Company Ltd. | $85.29 | 2022 | |
| Sunovion Pharmaceuticals INC. | $85.06 | 2022 | |
| Exact Sciences Corporation | $82.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Acadia Pharmaceuticals INC | $80.11 | 2024-2025 | Daybue |
| Sanofi-Aventis U.S. LLC | $79.07 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $69.10 | 2019-2022 | |
| Welch Allyn | $52.60 | 2021 | |
| Shield Therapeutics INC | $52.07 | 2023-2025 | Accrufer |
| Astellas Pharma US INC | $48.78 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $40.84 | 2023 | Gemtesa |
| Medtronic, INC. | $38.65 | 2023-2024 | Intellis Adaptivestim |
| Tris Pharma INC | $34.83 | 2024 | Dyanavel Xr |
| Genentech USA, INC. | $31.69 | 2019 | |
| Amneal Pharmaceuticals LLC | $29.18 | 2023 | Unithroid |
| Seqirus USA INC | $28.74 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Inari Medical, INC. | $28.06 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Circassia INC. | $26.76 | 2019-2020 | |
| Edwards Lifesciences Corporation | $21.53 | 2025 | |
| Sun Pharmaceutical Industries INC. | $17.89 | 2020 | |
| Phathom Pharmaceuticals, INC. | $14.68 | 2024 | Voquezna |
| Shire North American Group INC | $13.04 | 2019 | |
| Scilex Pharmaceuticals INC. | $12.35 | 2019 | |
| Eyevance Pharmaceuticals LLC | $11.53 | 2021 | |
| Gilead Sciences, INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Loper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.